60
Participants
Start Date
November 17, 2022
Primary Completion Date
March 31, 2027
Study Completion Date
April 30, 2027
GD2-SADA:177Lu-DOTA Complex
The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA, both will be administered as an IV infusion
RECRUITING
Memorial Sloan- Kettering Cancer Center, New York
ACTIVE_NOT_RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Case Western Reserve University, Cleveland, Cleveland
RECRUITING
Corewell Health-BAMF Health, Grand Rapids
RECRUITING
University of Wisconsin-Madison, Madison
NOT_YET_RECRUITING
University of Chicago, Chicago
RECRUITING
HonorHealth, Scottsdale
RECRUITING
City of Hope National Medical Center, Duarte
Lead Sponsor
Y-mAbs Therapeutics
INDUSTRY